Un buon prezzo.  in linea

dettagli dei prodotti

Created with Pixso. Casa. Created with Pixso. prodotti Created with Pixso.
Farmaci contro il cancro al polmone
Created with Pixso. Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Jascayd Nerandomilast 18mg Tablets For Idiopathic Pulmonary Fibrosis And Progressive Pulmonary Fibrosis Intervention

Marchio: Boehringer Ingelheim
Numero di modello: Compresse rivestite con film da 18 mg
MOQ: 1 pz
prezzo: Please contact a specialist WhatsApp:55342706
Tempi di consegna: Negoziabile
Termini di pagamento: Western Union, MoneyGram, T/T.
Informazioni dettagliate
Luogo di origine:
U.S.A.
Certificazione:
FDA NDA 218764
Specifica:
18 mg*60 compresse/scatola
Indicazioni:
Fibrosi polmonare idiopatica, fibrosi polmonare progressiva
Bersaglio:
PDE4B
Nome del prodotto:
Nerandomilast
Raccomandi:
Si prega di seguire i consigli del medico
Magazzinaggio:
Conservare a una temperatura compresa tra 20°C e 25°C, consentendo escursioni della temperatura ambi
Temperatura di conservazione:
da 20°C a 25°C
Intervallo di temperatura ambiente:
Da 15°C a 30°C
Forma di dosaggio:
Compressa rivestita
Forza della compressa:
18 mg
Dimensioni della confezione:
60 compresse/scatola
Enzima bersaglio:
PDE4B
Imballaggi particolari:
Negoziabile
Capacità di alimentazione:
Negoziabile
Evidenziare:

Jascayd Nerandomilast 18mg Idiopathic Pulmonary Fibrosis

,

Generic Nerandomilast 18mg Progressive Pulmonary Fibrosis

,

Jascayd BI 1015550 IPF PPF Tablets

Descrizione del prodotto
Jascayd Nerandomilast for Idiopathic Pulmonary Fibrosis & Progressive Pulmonary Fibrosis Intervention
Product Overview

For professional medical use only under physician supervision

Manufacturer: Boehringer Ingelheim International GmbH

Generic Name: Nerandomilast

Brand Name: Jascayd

FDA Approval: NDA 218764

Indications

Jascayd is a highly selective PDE4B targeted inhibitor with anti-fibrotic and immunomodulatory effects. It is indicated for adult patients diagnosed with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). May be used alone or in combination with standard anti-fibrotic agents such as pirfenidone or nintedanib to reduce lung capacity decline and delay disease progression.

Dosage and Administration

Standard Maintenance Dose: 18 mg orally twice daily, 12 hours apart. Swallow whole with room temperature water, before or after meals. Do not split, chew, or crush tablets.

  • Mild/Moderate Hepatic Impairment (Child-Pugh A/B): No dose adjustment required
  • Severe Hepatic Impairment & End-Stage Renal Disease: Insufficient safety data - not recommended

Missed Dose: Take immediately if remembered on the same day. If less than 4 hours until next dose, skip the missed dose. Do not take double dose.

Specifications

Film-coated oral tablets: 18 mg per tablet, 60 tablets per box

Contraindications
  • Patients with severe hypersensitivity to nerandomilast or any excipient component
  • Pregnant and breastfeeding women without professional risk-benefit assessment
Warnings and Precautions
  • Gastrointestinal Effects: Mild diarrhea, nausea, and stomach discomfort common during early treatment. Persistent severe GI reactions require medical evaluation and dose adjustment
  • Liver Function Monitoring: Regular liver function tests recommended during long-term use to monitor transient transaminase elevations
  • Drug Interactions: Metabolized by hepatic oxidation. Professional dose assessment required when used with strong CYP3A modulators
  • Fertility Considerations: Effective contraception recommended for patients of reproductive potential throughout treatment
Common Adverse Reactions (≥5% incidence)

Diarrhea, nausea, headache, fatigue, decreased appetite. Transient liver enzyme abnormalities frequently observed in laboratory tests.

Storage Requirements

Store at 20°C-25°C. Temporary exposure to 15°C-30°C acceptable. Protect from light. Keep in original packaging until use.